Forbes William P, EVP and Chief Development Officer, has engaged in a series of transactions primarily involving shares of Heron Therapeutics (HRTX), with no recorded purchases and a total of $3,337 in sales across 31 filings. The most recent activity occurred in late July 2026, with sales of $1,663 on July 31 and $1,674 on July 30, marking the only monetized transactions in the dataset. All other filings, including those for HRTX and XAIR (Beyond Air), reflect non-monetary transactions such as awards, dispositions, or mergers, with zero reported value.
The pattern indicates a consistent disposition of shares rather than accumulation, with no buys recorded in the available data. The transactions are concentrated in HRTX, with sporadic filings related to XAIR in late 2025, though none carried monetary value. The absence of recent buying activity and the focus on sales suggest a net reduction in holdings, though the dollar amounts involved are relatively modest. The lack of material transactions beyond mid-2026 leaves the current positioning unclear, but the historical data reflects a sell-side bias in Forbes’ trading history.
AI-assisted summary